Healthcare stocks have been hit hard lately, even after the recent recovery. Time to dive in for bargains? Edward Owens, arguably the best heathcare investor, is buying beaten down HMO and pharmas. These are his buys and sells during the second quarter of 2008.
Edward Owens sells Millennium Pharmaceuticals Inc., Unum Group during the 3-months ended 06/30/2008, according to the most recent filings of his investment company, Vanguard Health Care Fund. Edward Owens owns 79 stocks with a total value of $20.4 billion. These are the details of the buys and sells.
Added Positions: CVH, FRX, MRK, UNH,
Reduced Positions: BAX, CAH, GILD, JNJ, KMB, MDT,
Sold Out: MLNM, UNM,
For the details of Edward Owens's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Edward+Owens
Added: UnitedHealth Group Inc. (UNH, Financial)
Edward Owens added to his holdings in UnitedHealth Group Inc. by 140.78%. His purchase prices were between $26.01 and $37.25, with an estimated average price of $32.9. The impact to his portfolio due to this purchase was 1.26%. His holdings were 16,761,000 shares as of 06/30/2008.
UnitedHealth Group Inc. offers health care coverage and related services to help people achieve improved health and well-being through all stages of life. The company's products and services reflect a number of core capabilities including medical information management health benefit administration care coordination risk assessment and pricing health benefit design and provider contracting. With these capabilities it is able to provide comprehensive health care management services through organized health systems and insurance products. UnitedHealth Group Inc. has a market cap of $35.7 billion; its shares were traded at around $28.96 with a P/E ratio of 10.05 and P/S ratio of 0.45. The dividend yield of UnitedHealth Group Inc. stocks is 0.11%.
Added: Merck & Co. Inc. (MRK, Financial)
Edward Owens added to his holdings in Merck & Co. Inc. by 18.71%. His purchase prices were between $35.13 and $40.73, with an estimated average price of $38.4. The impact to his portfolio due to this purchase was 0.46%. His holdings were 15,896,100 shares as of 06/30/2008.
Merck & Co. Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891 Merck discovers develops manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. Merck & Co. Inc. has a market cap of $73.18 billion; its shares were traded at around $33.4 with a P/E ratio of 15.00 and P/S ratio of 2.96. The dividend yield of Merck & Co. Inc. stocks is 4.57%.
Added: Coventry Health Care Inc. (CVH, Financial)
Edward Owens added to his holdings in Coventry Health Care Inc. by 51.89%. His purchase prices were between $31.05 and $46.03, with an estimated average price of $41.8. The impact to his portfolio due to this purchase was 0.31%. His holdings were 6,151,500 shares as of 06/30/2008.
Coventry Health Care Inc. is a managed health care company operating health plans under the names Coventry Health Care Coventry Health and Life HealthAmerica HealthAssurance HealthCare USA Group Health Plan SouthCare Southern Health Carelink Health Plans and WellPath. The Company provides a full range of managed care products and services including health maintenance organization point-of-service preferred provider organization products and Medicare and Medicaid products. The Company also administers self-insured plans for large employer groups. Coventry Health Care Inc. has a market cap of $5.56 billion; its shares were traded at around $36.66 with a P/E ratio of 10.21 and P/S ratio of 0.49.
Added: Forest Laboratories Inc. (FRX, Financial)
Edward Owens added to his holdings in Forest Laboratories Inc. by 3.25%. His purchase prices were between $31.95 and $40.87, with an estimated average price of $35.2. The impact to his portfolio due to this purchase was 0.16%. His holdings were 30,133,000 shares as of 06/30/2008.
Forest Laboratories Inc. and its subsidiaries develop manufacture and sell both branded and generic forms of ethical drug products which require a physician's prescription as well as non-prescription pharmaceuticalproducts sold over-the-counter. Forest's most important United Statesproducts consist of branded ethical drug specialties marketed directly or to physicians by the company's Forest Pharmaceuticals Forest Therapeutics and Forest Specialty Sales salesforces. Forest Laboratories Inc. has a market cap of $11.04 billion; its shares were traded at around $35.54 with a P/E ratio of 12.02 and P/S ratio of 2.87.
Reduced: KimberlyClark Corp. (KMB, Financial)
Edward Owens reduced to his holdings in KimberlyClark Corp. by 21%. His sale prices were between $59.87 and $64.68, with an estimated average price of $62.6. The impact to his portfolio due to this sale was -0.02%. Edward Owens still held 376,300 shares as of 06/30/2008.
Kimberly-Clark Corporation is one of the leading consumer products companies. Its global tissue personal care and health care brands include Huggies Pull-Ups Kotex Depend Kleenex Scott Kimberly-Clark Safeskin Tecnol Kimwipes and Wypall. Other brands well known outside the U.S. include Andrex Scottex Page Popee and Kimbies. Kimberly-Clark also is a major producer of premium business correspondence and technical papers. (Company Press Release) KimberlyClark Corp. has a market cap of $24.96 billion; its shares were traded at around $58.94 with a P/E ratio of 14.48 and P/S ratio of 1.28. The dividend yield of KimberlyClark Corp. stocks is 4.01%.
Reduced: Johnson & Johnson (JNJ, Financial)
Edward Owens reduced to his holdings in Johnson & Johnson by 64%. His sale prices were between $63.57 and $67.78, with an estimated average price of $65.8. The impact to his portfolio due to this sale was -0.18%. Edward Owens still held 900,000 shares as of 06/30/2008.
Johnson & Johnson is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. The company's worldwide business is divided into three segments: Consumer; Pharmaceutical; and Professional. Johnson & Johnson has a market cap of $196.57 billion; its shares were traded at around $68.98 with a P/E ratio of 16.93 and P/S ratio of 3.06. The dividend yield of Johnson & Johnson stocks is 2.7%.
Reduced: Gilead Sciences Inc. (GILD, Financial)
Edward Owens reduced to his holdings in Gilead Sciences Inc. by 20.46%. His sale prices were between $50.64 and $55.32, with an estimated average price of $53.2. The impact to his portfolio due to this sale was -0.19%. Edward Owens still held 3,499,696 shares as of 06/30/2008.
Gilead Sciences Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases including viral infections fungal infections and bacterial infections and a specialized focus on cancer. They have expertise in liposomal drug delivery technology a technology that the company uses to develop drugsthat are safer easier for patients to tolerate and more effective. Gilead Sciences Inc. has a market cap of $50.98 billion; its shares were traded at around $53.84 with a P/E ratio of 30.66 and P/S ratio of 10.59.
Reduced: Baxter International Inc. (BAX, Financial)
Edward Owens reduced to his holdings in Baxter International Inc. by 23.4%. His sale prices were between $59.68 and $62.91, with an estimated average price of $61.3. The impact to his portfolio due to this sale was -0.26%. Edward Owens still held 3,600,000 shares as of 06/30/2008.
Baxter engages in the worldwide development manufacture and distribution of a diversified line of products systems and services used primarily in the health-care field. The company's products are used by hospitals clinical and medical research laboratories blood and dialysis centers rehabilitation centers nursing homes doctors' offices and by patients at home under physician supervision. Baxter International Inc. has a market cap of $43.35 billion; its shares were traded at around $68.91 with a P/E ratio of 24.11 and P/S ratio of 3.66. The dividend yield of Baxter International Inc. stocks is 1.27%.
Reduced: Cardinal Health Inc. (CAH, Financial)
Edward Owens reduced to his holdings in Cardinal Health Inc. by 46.14%. His sale prices were between $50.63 and $56.38, with an estimated average price of $53.8. The impact to his portfolio due to this sale was -0.6%. Edward Owens still held 5,136,708 shares as of 06/30/2008.
Cardinal Health Inc. is one of the leading providers of products and services to healthcare providers and manufacturers to help them improve the efficiency and quality of healthcare. These services and products include Pharmaceutical Distribution and Provider Services Medical-Surgical Products and Services Pharmaceutical Technologies and Services and Automation and Information Services. Cardinal Health Inc. has a market cap of $19.87 billion; its shares were traded at around $54.29 with a P/E ratio of 10.99 and P/S ratio of 0.21. The dividend yield of Cardinal Health Inc. stocks is 1.05%.
Reduced: Medtronic Inc. (MDT, Financial)
Edward Owens reduced to his holdings in Medtronic Inc. by 39.02%. His sale prices were between $46.81 and $51.35, with an estimated average price of $49.6. The impact to his portfolio due to this sale was -0.77%. Edward Owens still held 7,814,900 shares as of 06/30/2008.
Medtronic is the world's leading medical technology company pioneeringdevice-based therapies that restore health extend life and alleviate pain.Primary products include those for bradycardia pacing tachyarrhythmiamanagement atrial fibrillation management among others. Medtronic operates its business in one reportable segment that of manufacturing and selling device-based medical therapies. The company does business in more than 120 countries. The company's product lines include cardiac rhythm management neurological and spinal vascular and cardiac surgery. Medtronic Inc. has a market cap of $60 billion; its shares were traded at around $52.84 with a P/E ratio of 27.30 and P/S ratio of 4.40. The dividend yield of Medtronic Inc. stocks is 1.44%.
Sold Out: Millennium Pharmaceuticals Inc. (MLNM, Financial)
Edward Owens sold out his holdings in Millennium Pharmaceuticals Inc.. His sale prices were between $16.16 and $24.97, with an estimated average price of $23.7. The impact to his portfolio due to this sale was less than 0.01%.
Millennium Pharmaceuticals Inc. has a market cap of $ million; its shares were traded at around $24.97 .
Sold Out: Unum Group (UNM, Financial)
Edward Owens sold out his holdings in Unum Group. His sale prices were between $20.94 and $24.75, with an estimated average price of $23.2. The impact to his portfolio due to this sale was less than 0.01%.
UnumProvident is the industry leader in disability income protection and one of the top providers of supplemental benefits in the nation. The company's subsidiaries offer comprehensive insurance solutions to help protect against the financial effects of accident illness or death. Below are the countries in which we operate and the companies that offer products in each country. Unum Group has a market cap of $8.14 billion; its shares were traded at around $23.01 with a P/E ratio of 12.63 and P/S ratio of 0.76. The dividend yield of Unum Group stocks is 1.28%.
Edward Owens sells Millennium Pharmaceuticals Inc., Unum Group during the 3-months ended 06/30/2008, according to the most recent filings of his investment company, Vanguard Health Care Fund. Edward Owens owns 79 stocks with a total value of $20.4 billion. These are the details of the buys and sells.
Added Positions: CVH, FRX, MRK, UNH,
Reduced Positions: BAX, CAH, GILD, JNJ, KMB, MDT,
Sold Out: MLNM, UNM,
For the details of Edward Owens's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Edward+Owens
Added: UnitedHealth Group Inc. (UNH, Financial)
Edward Owens added to his holdings in UnitedHealth Group Inc. by 140.78%. His purchase prices were between $26.01 and $37.25, with an estimated average price of $32.9. The impact to his portfolio due to this purchase was 1.26%. His holdings were 16,761,000 shares as of 06/30/2008.
UnitedHealth Group Inc. offers health care coverage and related services to help people achieve improved health and well-being through all stages of life. The company's products and services reflect a number of core capabilities including medical information management health benefit administration care coordination risk assessment and pricing health benefit design and provider contracting. With these capabilities it is able to provide comprehensive health care management services through organized health systems and insurance products. UnitedHealth Group Inc. has a market cap of $35.7 billion; its shares were traded at around $28.96 with a P/E ratio of 10.05 and P/S ratio of 0.45. The dividend yield of UnitedHealth Group Inc. stocks is 0.11%.
Added: Merck & Co. Inc. (MRK, Financial)
Edward Owens added to his holdings in Merck & Co. Inc. by 18.71%. His purchase prices were between $35.13 and $40.73, with an estimated average price of $38.4. The impact to his portfolio due to this purchase was 0.46%. His holdings were 15,896,100 shares as of 06/30/2008.
Merck & Co. Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891 Merck discovers develops manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. Merck & Co. Inc. has a market cap of $73.18 billion; its shares were traded at around $33.4 with a P/E ratio of 15.00 and P/S ratio of 2.96. The dividend yield of Merck & Co. Inc. stocks is 4.57%.
Added: Coventry Health Care Inc. (CVH, Financial)
Edward Owens added to his holdings in Coventry Health Care Inc. by 51.89%. His purchase prices were between $31.05 and $46.03, with an estimated average price of $41.8. The impact to his portfolio due to this purchase was 0.31%. His holdings were 6,151,500 shares as of 06/30/2008.
Coventry Health Care Inc. is a managed health care company operating health plans under the names Coventry Health Care Coventry Health and Life HealthAmerica HealthAssurance HealthCare USA Group Health Plan SouthCare Southern Health Carelink Health Plans and WellPath. The Company provides a full range of managed care products and services including health maintenance organization point-of-service preferred provider organization products and Medicare and Medicaid products. The Company also administers self-insured plans for large employer groups. Coventry Health Care Inc. has a market cap of $5.56 billion; its shares were traded at around $36.66 with a P/E ratio of 10.21 and P/S ratio of 0.49.
Added: Forest Laboratories Inc. (FRX, Financial)
Edward Owens added to his holdings in Forest Laboratories Inc. by 3.25%. His purchase prices were between $31.95 and $40.87, with an estimated average price of $35.2. The impact to his portfolio due to this purchase was 0.16%. His holdings were 30,133,000 shares as of 06/30/2008.
Forest Laboratories Inc. and its subsidiaries develop manufacture and sell both branded and generic forms of ethical drug products which require a physician's prescription as well as non-prescription pharmaceuticalproducts sold over-the-counter. Forest's most important United Statesproducts consist of branded ethical drug specialties marketed directly or to physicians by the company's Forest Pharmaceuticals Forest Therapeutics and Forest Specialty Sales salesforces. Forest Laboratories Inc. has a market cap of $11.04 billion; its shares were traded at around $35.54 with a P/E ratio of 12.02 and P/S ratio of 2.87.
Reduced: KimberlyClark Corp. (KMB, Financial)
Edward Owens reduced to his holdings in KimberlyClark Corp. by 21%. His sale prices were between $59.87 and $64.68, with an estimated average price of $62.6. The impact to his portfolio due to this sale was -0.02%. Edward Owens still held 376,300 shares as of 06/30/2008.
Kimberly-Clark Corporation is one of the leading consumer products companies. Its global tissue personal care and health care brands include Huggies Pull-Ups Kotex Depend Kleenex Scott Kimberly-Clark Safeskin Tecnol Kimwipes and Wypall. Other brands well known outside the U.S. include Andrex Scottex Page Popee and Kimbies. Kimberly-Clark also is a major producer of premium business correspondence and technical papers. (Company Press Release) KimberlyClark Corp. has a market cap of $24.96 billion; its shares were traded at around $58.94 with a P/E ratio of 14.48 and P/S ratio of 1.28. The dividend yield of KimberlyClark Corp. stocks is 4.01%.
Reduced: Johnson & Johnson (JNJ, Financial)
Edward Owens reduced to his holdings in Johnson & Johnson by 64%. His sale prices were between $63.57 and $67.78, with an estimated average price of $65.8. The impact to his portfolio due to this sale was -0.18%. Edward Owens still held 900,000 shares as of 06/30/2008.
Johnson & Johnson is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. The company's worldwide business is divided into three segments: Consumer; Pharmaceutical; and Professional. Johnson & Johnson has a market cap of $196.57 billion; its shares were traded at around $68.98 with a P/E ratio of 16.93 and P/S ratio of 3.06. The dividend yield of Johnson & Johnson stocks is 2.7%.
Reduced: Gilead Sciences Inc. (GILD, Financial)
Edward Owens reduced to his holdings in Gilead Sciences Inc. by 20.46%. His sale prices were between $50.64 and $55.32, with an estimated average price of $53.2. The impact to his portfolio due to this sale was -0.19%. Edward Owens still held 3,499,696 shares as of 06/30/2008.
Gilead Sciences Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases including viral infections fungal infections and bacterial infections and a specialized focus on cancer. They have expertise in liposomal drug delivery technology a technology that the company uses to develop drugsthat are safer easier for patients to tolerate and more effective. Gilead Sciences Inc. has a market cap of $50.98 billion; its shares were traded at around $53.84 with a P/E ratio of 30.66 and P/S ratio of 10.59.
Reduced: Baxter International Inc. (BAX, Financial)
Edward Owens reduced to his holdings in Baxter International Inc. by 23.4%. His sale prices were between $59.68 and $62.91, with an estimated average price of $61.3. The impact to his portfolio due to this sale was -0.26%. Edward Owens still held 3,600,000 shares as of 06/30/2008.
Baxter engages in the worldwide development manufacture and distribution of a diversified line of products systems and services used primarily in the health-care field. The company's products are used by hospitals clinical and medical research laboratories blood and dialysis centers rehabilitation centers nursing homes doctors' offices and by patients at home under physician supervision. Baxter International Inc. has a market cap of $43.35 billion; its shares were traded at around $68.91 with a P/E ratio of 24.11 and P/S ratio of 3.66. The dividend yield of Baxter International Inc. stocks is 1.27%.
Reduced: Cardinal Health Inc. (CAH, Financial)
Edward Owens reduced to his holdings in Cardinal Health Inc. by 46.14%. His sale prices were between $50.63 and $56.38, with an estimated average price of $53.8. The impact to his portfolio due to this sale was -0.6%. Edward Owens still held 5,136,708 shares as of 06/30/2008.
Cardinal Health Inc. is one of the leading providers of products and services to healthcare providers and manufacturers to help them improve the efficiency and quality of healthcare. These services and products include Pharmaceutical Distribution and Provider Services Medical-Surgical Products and Services Pharmaceutical Technologies and Services and Automation and Information Services. Cardinal Health Inc. has a market cap of $19.87 billion; its shares were traded at around $54.29 with a P/E ratio of 10.99 and P/S ratio of 0.21. The dividend yield of Cardinal Health Inc. stocks is 1.05%.
Reduced: Medtronic Inc. (MDT, Financial)
Edward Owens reduced to his holdings in Medtronic Inc. by 39.02%. His sale prices were between $46.81 and $51.35, with an estimated average price of $49.6. The impact to his portfolio due to this sale was -0.77%. Edward Owens still held 7,814,900 shares as of 06/30/2008.
Medtronic is the world's leading medical technology company pioneeringdevice-based therapies that restore health extend life and alleviate pain.Primary products include those for bradycardia pacing tachyarrhythmiamanagement atrial fibrillation management among others. Medtronic operates its business in one reportable segment that of manufacturing and selling device-based medical therapies. The company does business in more than 120 countries. The company's product lines include cardiac rhythm management neurological and spinal vascular and cardiac surgery. Medtronic Inc. has a market cap of $60 billion; its shares were traded at around $52.84 with a P/E ratio of 27.30 and P/S ratio of 4.40. The dividend yield of Medtronic Inc. stocks is 1.44%.
Sold Out: Millennium Pharmaceuticals Inc. (MLNM, Financial)
Edward Owens sold out his holdings in Millennium Pharmaceuticals Inc.. His sale prices were between $16.16 and $24.97, with an estimated average price of $23.7. The impact to his portfolio due to this sale was less than 0.01%.
Millennium Pharmaceuticals Inc. has a market cap of $ million; its shares were traded at around $24.97 .
Sold Out: Unum Group (UNM, Financial)
Edward Owens sold out his holdings in Unum Group. His sale prices were between $20.94 and $24.75, with an estimated average price of $23.2. The impact to his portfolio due to this sale was less than 0.01%.
UnumProvident is the industry leader in disability income protection and one of the top providers of supplemental benefits in the nation. The company's subsidiaries offer comprehensive insurance solutions to help protect against the financial effects of accident illness or death. Below are the countries in which we operate and the companies that offer products in each country. Unum Group has a market cap of $8.14 billion; its shares were traded at around $23.01 with a P/E ratio of 12.63 and P/S ratio of 0.76. The dividend yield of Unum Group stocks is 1.28%.
